Lymphoma Clinical Trials in Vancouver, British Columbia

15 recruitingVancouver, British Columbia, Canada

Showing 115 of 15 trials

Recruiting
Phase 3

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
National Cancer Institute (NCI)247 enrolled627 locationsNCT04269902
Recruiting
Phase 3

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
National Cancer Institute (NCI)1,875 enrolled399 locationsNCT05675410
Recruiting
Phase 3

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Marginal Zone LymphomaRelapsed/Refractory Follicular Lymphoma
BeiGene780 enrolled277 locationsNCT05100862
Recruiting
Phase 1Phase 2

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+6 more
BeOne Medicines614 enrolled120 locationsNCT05006716
Recruiting

Economic Analysis of Early vs Delayed Therapy in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma:

Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Canadian Cancer Trials Group247 enrolled8 locationsNCT05371808
Recruiting
Phase 3

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Mixed Phenotype Acute LeukemiaB Acute Lymphoblastic LeukemiaB Lymphoblastic Lymphoma+2 more
Children's Oncology Group5,951 enrolled230 locationsNCT03959085
Recruiting
Phase 2

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

Advanced Solid TumorsMultiple MyelomaLymphoma, Non-Hodgkin
Canadian Cancer Trials Group720 enrolled10 locationsNCT03297606
Recruiting
Phase 2

Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma

Non-Hodgkin Lymphoma
Canadian Cancer Trials Group30 enrolled8 locationsNCT05998642
Recruiting
Phase 2

Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

Hodgkin Lymphoma
Canadian Cancer Trials Group84 enrolled18 locationsNCT05180097
Recruiting
Early Phase 1

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

Lymphoma, B-Cell
Canadian Cancer Trials Group18 enrolled4 locationsNCT04161248
Recruiting
Phase 1

TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas

LymphomaLymphoma, Non-Hodgkin
Treeline Biosciences, Inc.180 enrolled11 locationsNCT07082803
Recruiting
Phase 1

CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaMantle Cell Lymphoma+5 more
British Columbia Cancer Agency24 enrolled7 locationsNCT06208735
Recruiting
Phase 1

A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma

Lymphoma
Treeline Biosciences, Inc.50 enrolled5 locationsNCT06733441
Recruiting
Phase 1Phase 2

CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies

Acute Lymphoblastic LeukemiaChronic Lymphocytic LeukemiaNon-Hodgkin's Lymphoma
Ottawa Hospital Research Institute60 enrolled3 locationsNCT03765177
Recruiting
Phase 2

Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma

Mantle Cell Lymphoma
University Health Network, Toronto105 enrolled5 locationsNCT04566887